 Neuroblastoma
"Neuroblastoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
| Descriptor ID |
D009447
|
| MeSH Number(s) |
C04.557.465.625.600.590.650.550 C04.557.470.670.590.650.550 C04.557.580.625.600.590.650.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neuroblastoma".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Neoplasms, Germ Cell and Embryonal [C04.557.465]
- Neuroectodermal Tumors [C04.557.465.625]
- Neoplasms, Neuroepithelial [C04.557.465.625.600]
- Neuroectodermal Tumors, Primitive [C04.557.465.625.600.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.465.625.600.590.650]
- Neuroblastoma [C04.557.465.625.600.590.650.550]
- Neoplasms, Glandular and Epithelial [C04.557.470]
- Neoplasms, Neuroepithelial [C04.557.470.670]
- Neuroectodermal Tumors, Primitive [C04.557.470.670.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.470.670.590.650]
- Neuroblastoma [C04.557.470.670.590.650.550]
- Neoplasms, Nerve Tissue [C04.557.580]
- Neuroectodermal Tumors [C04.557.580.625]
- Neoplasms, Neuroepithelial [C04.557.580.625.600]
- Neuroectodermal Tumors, Primitive [C04.557.580.625.600.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.580.625.600.590.650]
- Neuroblastoma [C04.557.580.625.600.590.650.550]
Below are MeSH descriptors whose meaning is more specific than "Neuroblastoma".
This graph shows the total number of publications written about "Neuroblastoma" by people in this website by year, and whether "Neuroblastoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 1 | 3 | | 1996 | 4 | 3 | 7 | | 1998 | 1 | 1 | 2 | | 1999 | 0 | 3 | 3 | | 2000 | 1 | 1 | 2 | | 2001 | 2 | 1 | 3 | | 2003 | 1 | 2 | 3 | | 2004 | 1 | 0 | 1 | | 2005 | 2 | 0 | 2 | | 2006 | 5 | 4 | 9 | | 2007 | 6 | 2 | 8 | | 2008 | 5 | 0 | 5 | | 2009 | 4 | 1 | 5 | | 2010 | 4 | 0 | 4 | | 2011 | 2 | 0 | 2 | | 2012 | 0 | 3 | 3 | | 2013 | 1 | 2 | 3 | | 2014 | 1 | 1 | 2 | | 2015 | 2 | 0 | 2 | | 2016 | 3 | 1 | 4 | | 2017 | 3 | 3 | 6 | | 2018 | 3 | 3 | 6 | | 2019 | 2 | 1 | 3 | | 2020 | 3 | 0 | 3 | | 2021 | 4 | 0 | 4 | | 2022 | 6 | 0 | 6 | | 2023 | 3 | 0 | 3 | | 2024 | 7 | 2 | 9 | | 2025 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Neuroblastoma" by people in Profiles.
-
DuBois SG, Ogawa C, Moreno L, Moss? YP, Fischer M, Ryan AL, Vo KT, De Wilde B, Rubio-San-Simon A, Macy ME, Howell L, Shusterman S, Corradini N, Luksch R, Aerts I, Foster JH, Weiss BD, Karthik CP, Yuen E, Avsar E, Park JR, Marachelian A. A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751.
-
Voeller J, Katzenstein HM, Naranjo A, Tenney SC, Chen L, London WB, Handler MH, Schmidt ML, Shimada H, Hogarty MD, Gastier-Foster J, Park JR, Cohn SL, Maris JM, Bagatell R, Twist CJ. Outcomes of patients with intermediate-risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531. Pediatr Blood Cancer. 2025 Jan; 72(1):e31407.
-
Hamilton AK, Radaoui AB, Tsang M, Martinez D, Conkrite KL, Patel K, Sidoli S, Delaidelli A, Modi A, Rokita JL, Lane MV, Hartnett N, Lopez RD, Zhang B, Zhong C, Ennis B, Miller DP, Brown MA, Rathi KS, Raman P, Pogoriler J, Bhatti T, Pawel B, Glisovic-Aplenc T, Teicher B, Erickson SW, Earley EJ, Bosse KR, Sorensen PH, Krytska K, Mosse YP, Havenith KE, Zammarchi F, van Berkel PH, Smith MA, Garcia BA, Maris JM, Diskin SJ. A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma. Cancer Cell. 2024 Nov 11; 42(11):1970-1982.e7.
-
Teke M, Rich BS, Walther A, Schwartz D, McDuffie LA, Butera G, Roach JP, Rothstein DH, Lal DR, Riehle K, Espinoza A, Cost N, Tracy E, Rodeberg D, Lautz T, Aldrink JH, Brown EG. A Comparison of Commonly Utilized Diagnostic Biopsy Techniques for Pediatric Patients With Cancer: A Systematic Review by the APSA Cancer Committee. J Pediatr Surg. 2025 Feb; 60(2):161893.
-
Rozen EJ, Frantz W, Wigglesworth K, Vessella T, Zhou HS, Shohet JM. Blockade of Discoidin Domain Receptor Signaling with Sitravatinib Reveals DDR2 as a Mediator of Neuroblastoma Pathogenesis and Metastasis. Mol Cancer Ther. 2024 Aug 01; 23(8):1124-1138.
-
Bagatell R, Park JR, Acharya S, Aldrink J, Allison J, Alva E, Arndt C, Benedetti D, Brown E, Cho S, Church A, Davidoff A, Desai AV, DuBois S, Fair D, Farinhas J, Harrison D, Huang F, Iskander P, Kreissman S, Macy M, Na B, Pashankar F, Pendyala P, Pinto N, Polites S, Rabah R, Shimada H, Slatnick L, Sokol E, Twist C, Vo K, Watt T, Wolden S, Zage P, Schonfeld R, Hang L. Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 08; 22(6):413-433.
-
Barr EK, Naranjo A, Twist CJ, Tenney SC, Schmidt ML, London WB, Gastier-Foster J, Adkins ES, Mattei P, Handler MH, Matthay KK, Park JR, Maris JM, Desai AV, Cohn SL. Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531. Pediatr Blood Cancer. 2024 Aug; 71(8):e31089.
-
Basavalingu D, Sadic M, Cheeney S, Parisi MT. A Rare Case of Abnormal Diffuse Brain Uptake on an 123I MIBG Scan in a Patient With High-Risk Neuroblastoma. Clin Nucl Med. 2024 May 01; 49(5):438-441.
-
Vessella T, Xiang S, Xiao C, Stilwell M, Fok J, Shohet J, Rozen E, Zhou HS, Wen Q. DDR2 signaling and mechanosensing orchestrate neuroblastoma cell fate through different transcriptome mechanisms. FEBS Open Bio. 2024 May; 14(5):867-882.
-
Mullegama SV, Kiernan KA, Torti E, Pavlovsky E, Tilton N, Sekula A, Gao H, Alaimo JT, Engleman K, Rush ET, Blocker K, Dipple KM, Fettig VM, Hare H, Glass I, Grange DK, Griffin M, Phornphutkul C, Massingham L, Mehta L, Miller DE, Thies J, Merritt JL, Muller E, Osmond M, Sawyer SL, Slaugh R, Hickey RE, Wolf B, Choudhary S, Simonovic M, Zhang Y, Palculict TB, Telegrafi A, Carere DA, Wentzensen IM, Morrow MM, Monaghan KG, Yang J, Juusola J. De novo missense variants in exon 9 of SEPHS1 cause a neurodevelopmental condition with developmental delay, poor growth, hypotonia, and dysmorphic features. Am J Hum Genet. 2024 04 04; 111(4):778-790.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|